

Supplementary Materials for
Consolidated Financial Results
for the 3rd Quarter of Fiscal Year 2011. 12



CHUGAI PHARMACEUTICAL CO., LTD.

 A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
2. Amounts shown in Financial Highlights, Extraordinary Gains and Losses, Statements of Revenues, Balance Sheets, Cash Flows and Capital Expenditures of this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
3. Exchange rates used for each period are as follows.

(Yen)

| Fx rates | FY2008 | FY2009 | FY2010 | | | | FY2011 | | | | Revised Forecast (released on July 21) |
|----------|-------------|-------------|---------|---------|---------|---------|---------|---------|---------|---------|---|
| | 1-12 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | FY2011 |
| | (Full-year) | (Full-year) | (YTD) | 7-12 |
| | average | average | average | average | average | average | average | average | average | average | (2nd Half) forecast |
| CHF | 95.54 | 86.20 | 85.80 | 84.42 | 84.00 | 84.17 | 87.30 | 90.38 | 91.62 | - | 95.00 |
| EUR | 151.38 | 130.10 | 125.58 | 121.21 | 117.66 | 116.32 | 112.36 | 114.86 | 113.25 | - | 110.00 |
| USD | 103.44 | 93.60 | 90.69 | 91.41 | 89.56 | 87.81 | 82.23 | 81.93 | 80.55 | - | 85.00 |
| GBP | 189.85 | 145.99 | 141.62 | 139.45 | 137.32 | 135.65 | 131.71 | 132.43 | 130.03 | - | 131.00 |

Financial Highlights (YTD)

(Billions of Yen)

| | FY2008 | FY2009 | FY2010 | | | | FY2011 | | | | | | | | Revised Forecast (released on July 21) | | | | | |
|---------------------------------|--------|--------|-----------|-----------|-------|-------|--------|---------|-------|------------|-------|------------|-----|------------|--|------------|-------------------|------------|-----------|------------|
| | | | 1-12 | | 1-3 | | 1-6 | | 1-3 | | 1-6 | | 1-9 | | 1-12 | | 1-6 | | 1-12 | |
| | | | Full-year | Full-year | YTD | YTD | YTD | YTD | YTD | Change (%) | YTD | Change (%) | YTD | Change (%) | YTD | Change (%) | Half-year(Actual) | Change (%) | Full-year | Change (%) |
| | | | | | | | | | | | | | | | | | | | | |
| Revenues | 326.9 | 428.9 | 87.1 | 182.4 | 276.1 | 379.5 | 85.7 | (1.6) | 181.9 | (0.3) | 276.0 | (0.0) | - | - | 181.9 | (0.3) | 395.2 | +4.1 | | |
| Sales | 321.8 | 419.1 | 86.2 | 180.6 | 273.3 | 375.6 | 80.4 | (6.7) | 174.8 | (3.2) | 267.5 | (2.1) | - | - | 174.8 | (3.2) | 384.5 | +2.4 | | |
| excl. Tamiflu | 313.4 | 342.9 | 75.4 | 168.6 | 257.4 | 357.4 | 76.2 | +1.1 | 170.2 | +0.9 | 261.2 | +1.5 | - | - | 170.2 | +0.9 | 374.3 | +4.7 | | |
| Tamiflu | 8.4 | 76.2 | 10.8 | 12.0 | 15.8 | 18.2 | 4.2 | (61.1) | 4.6 | (61.7) | 6.3 | (60.1) | - | - | 4.6 | (61.7) | 10.2 | (44.0) | | |
| Ordinary sales | 7.1 | 36.2 | 1.4 | 1.4 | 1.4 | 1.6 | 3.7 | +164.3 | 4.1 | +192.9 | 4.1 | +192.9 | - | - | 4.1 | +192.9 | 6.7 | +318.8 | | |
| Govt. stockpile etc. | 1.3 | 40.0 | 9.5 | 10.6 | 14.4 | 16.6 | 0.5 | (94.7) | 0.5 | (95.3) | 2.2 | (84.7) | - | - | 0.5 | (95.3) | 3.5 | (78.9) | | |
| Other operating revenues | 5.1 | 9.8 | 0.9 | 1.7 | 2.8 | 3.9 | 5.3 | +488.9 | 7.2 | +323.5 | 8.5 | +203.6 | - | - | 7.2 | +323.5 | 10.7 | +174.4 | | |
| Cost of sales | 127.0 | 192.9 | 41.1 | 80.5 | 119.6 | 162.4 | 35.1 | (14.6) | 74.5 | (7.5) | 115.4 | (3.5) | - | - | 74.5 | (7.5) | 167.2 | +3.0 | | |
| (% of Sales) | 39.5 | 46.0 | 47.7 | 44.6 | 43.8 | 43.2 | 43.7 | - | 42.6 | - | 43.1 | - | - | - | 42.6 | - | 43.5 | - | | |
| Gross profit | 199.9 | 236.1 | 46.0 | 101.8 | 156.5 | 217.1 | 50.6 | +10.0 | 107.4 | +5.5 | 160.7 | +2.7 | - | - | 107.4 | +5.5 | 228.0 | +5.0 | | |
| (% of Revenues) | 61.2 | 55.0 | 52.8 | 55.8 | 56.7 | 57.2 | 59.0 | - | 59.0 | - | 58.2 | - | - | - | 59.0 | - | 57.7 | - | | |
| SG&A (excl. R&D) expenses | 95.1 | 98.2 | 22.8 | 47.7 | 71.4 | 96.2 | 22.0 | (3.5) | 45.3 | (5.0) | 69.4 | (2.8) | - | - | 45.3 | (5.0) | 98.0 | +1.9 | | |
| (% of Revenues) | 29.1 | 22.9 | 26.2 | 26.2 | 25.9 | 25.3 | 25.7 | - | 24.9 | - | 25.1 | - | - | - | 24.9 | - | 24.8 | - | | |
| R&D expenses | 53.2 | 55.3 | 12.2 | 26.6 | 39.9 | 54.7 | 13.0 | +6.6 | 26.9 | +1.1 | 41.2 | +3.3 | - | - | 26.9 | +1.1 | 58.0 | +6.0 | | |
| (% of Revenues) | 16.3 | 12.9 | 14.0 | 14.6 | 14.5 | 14.4 | 15.2 | - | 14.8 | - | 14.9 | - | - | - | 14.8 | - | 14.7 | - | | |
| Operating income | 51.6 | 82.6 | 11.1 | 27.6 | 45.1 | 66.2 | 15.6 | +40.5 | 35.2 | +27.5 | 50.0 | +10.9 | - | - | 35.2 | +27.5 | 72.0 | +8.8 | | |
| (% of Revenues) | 15.8 | 19.3 | 12.7 | 15.1 | 16.3 | 17.4 | 18.2 | - | 19.4 | - | 18.1 | - | - | - | 19.4 | - | 18.2 | - | | |
| Non-operating income | 9.9 | 9.4 | 1.3 | 3.0 | 2.2 | 2.4 | 2.1 | +61.5 | 1.3 | (56.7) | 3.3 | +50.0 | - | - | 1.3 | (56.7) | - | - | | |
| Non-operating expenses | 4.2 | 1.6 | 0.3 | 4.4 | 3.0 | 3.5 | 1.0 | +233.3 | 0.4 | (90.9) | 2.2 | (26.7) | - | - | 0.4 | (90.9) | - | - | | |
| Ordinary income | 57.3 | 90.4 | 12.1 | 26.2 | 44.3 | 65.1 | 16.7 | +38.0 | 36.2 | +38.2 | 51.1 | +15.3 | - | - | 36.2 | +38.2 | 73.1 | +12.3 | | |
| (% of Revenues) | 17.5 | 21.1 | 13.9 | 14.4 | 16.0 | 17.2 | 19.5 | - | 19.9 | - | 18.5 | - | - | - | 19.9 | - | 18.5 | - | | |
| Extraordinary gain | 7.3 | 0.3 | 0.1 | 0.1 | 0.1 | 0.6 | - | (100.0) | - | (100.0) | 0.0 | (100.0) | - | - | - | (100.0) | - | - | | |
| Extraordinary loss | 1.4 | 1.3 | 0.0 | 0.1 | 0.1 | 0.0 | 7.1 | - | 7.6 | +7,500.0 | 9.1 | +9,000.0 | - | - | 7.6 | +7,500.0 | - | - | | |
| Income before income taxes etc. | 63.1 | 89.4 | 12.1 | 26.1 | 44.3 | 65.7 | 9.6 | (20.7) | 28.6 | +9.6 | 42.0 | (5.2) | - | - | 28.6 | +9.6 | - | - | | |
| (% of Revenues) | 19.3 | 20.8 | 13.9 | 14.3 | 16.0 | 17.3 | 11.2 | - | 15.7 | - | 15.2 | - | - | - | 15.7 | - | - | - | | |
| Net income | 39.3 | 56.6 | 7.9 | 16.4 | 28.1 | 41.4 | 5.0 | (36.7) | 17.1 | +4.3 | 27.1 | (3.6) | - | - | 17.1 | +4.3 | 37.0 | (10.6) | | |
| (% of Revenues) | 12.0 | 13.2 | 9.1 | 9.0 | 10.2 | 10.9 | 5.8 | - | 9.4 | - | 9.8 | - | - | - | 9.4 | - | 9.4 | - | | |

Extraordinary Gains and Losses

Extraordinary Losses

(Billions of Yen)

| | Amount | Description |
|--|--------|--|
| Loss on disaster | 7.4 | <ul style="list-style-type: none"> •Expenses due to impact of the Great East Japan Earthquake, offsetting with estimated insurance proceeds. •Most of the damage were incurred at Utsunomiya Plant. The following are included in the amount. <ul style="list-style-type: none"> -loss on and restoration costs for damaged PP&E -demolition costs for damaged assets -loss on inventories -fixed costs during shutdown, etc. |
| Loss on adjustment for changes of accounting standard for asset retirement obligations | 1.0 | The impact at beginning of the year due to application of "Accounting Standards for Asset Retirement Obligations" |

Statements of Revenues (YTD)

(Billions of Yen)

| | | | FY2010 | | | | FY2011 | | | | | | Revised Forecast (released on July 21) | | | | | |
|--|-----------|-----------|--------|-------|-------|-------|--------|------------|-------|------------|-------|------------|--|------------|-------------------|------------|-----------|------------|
| | FY2008 | FY2009 | FY2010 | | | | FY2011 | | | | | | FY2011 | | | | | |
| | 1-12 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | Change (%) | 1-6 | Change (%) | 1-9 | Change (%) | 1-12 | Change (%) | 1-6 | Change (%) | 1-12 | Change (%) |
| | Full-year | Full-year | YTD | YTD | YTD | YTD | YTD | | YTD | | YTD | | YTD | | Half-year(Actual) | | Full-year | |
| Sales | 321.8 | 419.1 | 86.2 | 180.6 | 273.3 | 375.6 | 80.4 | (6.7) | 174.8 | (3.2) | 267.5 | (2.1) | - | - | 174.8 | (3.2) | 384.5 | +2.4 |
| Excl. Tamiflu | 313.4 | 342.9 | 75.4 | 168.6 | 257.4 | 357.4 | 76.2 | +1.1 | 170.2 | +0.9 | 261.2 | +1.5 | - | - | 170.2 | +0.9 | 374.3 | +4.7 |
| Domestic | 279.9 | 309.3 | 68.0 | 150.6 | 231.3 | 324.4 | 70.2 | +3.2 | 150.9 | +0.2 | 227.8 | (1.5) | - | - | 150.9 | +0.2 | 337.2 | +3.9 |
| Oncology field | 102.3 | 123.7 | 28.8 | 64.6 | 100.1 | 141.2 | 31.0 | +7.6 | 67.9 | +5.1 | 101.5 | +1.4 | - | - | 67.9 | +5.1 | 150.6 | +6.7 |
| Avastin | 20.1 | 34.9 | 10.3 | 23.3 | 36.8 | 52.6 | 12.5 | +21.4 | 26.4 | +13.3 | 40.2 | +9.2 | - | - | 26.4 | +13.3 | 62.4 | +18.6 |
| Herceptin | 23.7 | 29.7 | 5.7 | 12.1 | 18.3 | 25.3 | 5.6 | (1.8) | 13.9 | +14.9 | 18.7 | +2.2 | - | - | 13.9 | +14.9 | 24.6 | (2.8) |
| Rituxan | 20.5 | 21.1 | 4.5 | 10.3 | 16.1 | 23.0 | 4.9 | +8.9 | 10.4 | +1.0 | 16.2 | +0.6 | - | - | 10.4 | +1.0 | 23.5 | +2.2 |
| Xeloda | 4.8 | 6.6 | 2.3 | 5.1 | 7.8 | 10.7 | 2.3 | +0.0 | 4.9 | (3.9) | 7.4 | (5.1) | - | - | 4.9 | (3.9) | 11.7 | +9.3 |
| Neutrogin | 12.0 | 11.3 | 2.0 | 4.6 | 7.2 | 10.4 | 1.8 | (10.0) | 4.1 | (10.9) | 6.6 | (8.3) | - | - | 4.1 | (10.9) | 10.1 | (2.9) |
| Tarceva | 4.5 | 5.8 | 1.4 | 3.5 | 5.5 | 7.9 | 1.7 | +21.4 | 3.8 | +8.6 | 5.8 | +5.5 | - | - | 3.8 | +8.6 | 8.8 | +11.4 |
| Femara | 1.7 | 2.4 | 0.6 | 1.4 | 2.2 | 3.2 | 0.8 | +33.3 | 1.7 | +21.4 | 2.6 | +18.2 | - | - | 1.7 | +21.4 | 3.8 | +18.8 |
| Kytril | 10.9 | 8.6 | 1.5 | 3.0 | 4.3 | 5.5 | 0.8 | (46.7) | 1.7 | (43.3) | 2.5 | (41.9) | - | - | 1.7 | (43.3) | 3.7 | (32.7) |
| Other products | 4.1 | 3.3 | 0.6 | 1.3 | 1.9 | 2.5 | 0.5 | (16.7) | 1.0 | (23.1) | 1.5 | (21.1) | - | - | 1.0 | (23.1) | 2.0 | (20.0) |
| Bone and joint diseases field | 50.0 | 57.6 | 13.0 | 28.6 | 44.1 | 62.6 | 14.0 | +7.7 | 30.4 | +6.3 | 47.2 | +7.0 | - | - | 30.4 | +6.3 | 69.0 | +10.2 |
| Actemra | 3.4 | 8.4 | 2.6 | 5.8 | 9.4 | 14.1 | 3.5 | +34.6 | 7.6 | +31.0 | 12.1 | +28.7 | - | - | 7.6 | +31.0 | 19.9 | +41.1 |
| Evista | 16.5 | 17.9 | 3.8 | 8.6 | 13.1 | 18.7 | 3.8 | +0.0 | 8.4 | (2.3) | 13.2 | +0.8 | - | - | 8.4 | (2.3) | 17.5 | (6.4) |
| Suvenyl | 12.0 | 13.7 | 2.9 | 6.4 | 9.7 | 13.6 | 2.6 | (10.3) | 6.0 | (6.3) | 9.3 | (4.1) | - | - | 6.0 | (6.3) | 13.7 | +0.7 |
| Alfarol | 13.7 | 13.6 | 2.7 | 5.9 | 8.8 | 12.3 | 2.6 | (3.7) | 5.4 | (8.5) | 8.2 | (6.8) | - | - | 5.4 | (8.5) | 11.1 | (9.8) |
| Edirol * | - | - | - | - | - | - | - | - | 0.6 | - | 0.8 | - | - | - | 0.6 | - | 2.1 | - |
| Other products | 4.5 | 3.9 | 1.0 | 1.9 | 3.1 | 4.0 | 1.5 | +50.0 | 2.4 | +26.3 | 3.6 | +16.1 | - | - | 2.4 | +26.3 | 4.8 | +20.0 |
| Renal diseases field | 61.3 | 61.0 | 12.5 | 27.2 | 41.7 | 57.4 | 11.4 | (8.8) | 24.3 | (10.7) | 36.9 | (11.5) | - | - | 24.3 | (10.7) | 58.9 | +2.6 |
| Epogin | 44.9 | 44.4 | 8.7 | 19.0 | 29.2 | 40.0 | 7.5 | (13.8) | 16.6 | (12.6) | 22.5 | (22.9) | - | - | 16.6 | (12.6) | 30.5 | (23.8) |
| Mircera * | - | - | - | - | - | - | - | - | - | - | 2.8 | - | - | - | - | - | 12.4 | - |
| Oxarol | 10.0 | 10.6 | 2.5 | 5.6 | 8.6 | 12.0 | 2.8 | +12.0 | 5.8 | +3.6 | 8.8 | +2.3 | - | - | 5.8 | +3.6 | 12.4 | +3.3 |
| Renagel | 5.7 | 5.3 | 1.1 | 2.3 | 3.5 | 4.9 | 1.1 | +0.0 | 1.7 | (26.1) | 2.3 | (34.3) | - | - | 1.7 | (26.1) | 3.1 | (36.7) |
| Other products | 0.7 | 0.7 | 0.2 | 0.3 | 0.4 | 0.5 | 0.1 | (50.0) | 0.2 | (33.3) | 0.4 | +0.0 | - | - | 0.2 | (33.3) | 0.5 | +0.0 |
| Transplant, Immunology & Infectious diseases field | 24.0 | 26.2 | 5.3 | 11.9 | 18.3 | 25.8 | 5.5 | +3.8 | 11.5 | (3.4) | 17.0 | (7.1) | - | - | 11.5 | (3.4) | 25.1 | (2.7) |
| Pegasys | 9.7 | 11.1 | 2.2 | 4.8 | 7.4 | 10.5 | 2.2 | +0.0 | 4.4 | (8.3) | 6.3 | (14.9) | - | - | 4.4 | (8.3) | 10.3 | (1.9) |
| Copegus | 4.2 | 4.9 | 0.9 | 2.0 | 3.1 | 4.5 | 0.9 | +0.0 | 1.9 | (5.0) | 2.6 | (16.1) | - | - | 1.9 | (5.0) | 4.4 | (2.2) |
| CellCept | 4.0 | 4.4 | 1.0 | 2.3 | 3.6 | 5.2 | 1.2 | +20.0 | 2.6 | +13.0 | 4.1 | +13.9 | - | - | 2.6 | +13.0 | 5.8 | +11.5 |
| Rocephin | 5.9 | 5.5 | 1.1 | 2.6 | 3.9 | 5.4 | 1.1 | +0.0 | 2.4 | (7.7) | 3.7 | (5.1) | - | - | 2.4 | (7.7) | 4.4 | (18.5) |
| Other products | 0.3 | 0.3 | 0.1 | 0.1 | 0.2 | 0.3 | 0.1 | +0.0 | 0.2 | +100.0 | 0.2 | +0.0 | - | - | 0.2 | +100.0 | 0.3 | +0.0 |
| Others field | 42.3 | 40.9 | 8.3 | 18.3 | 27.1 | 37.4 | 8.3 | +0.0 | 16.8 | (8.2) | 25.2 | (7.0) | - | - | 16.8 | (8.2) | 33.6 | (10.2) |
| Sigmart | 15.0 | 14.7 | 2.9 | 6.3 | 9.4 | 13.0 | 2.7 | (6.9) | 5.7 | (9.5) | 8.3 | (11.7) | - | - | 5.7 | (9.5) | 11.6 | (10.8) |
| Other products | 27.3 | 26.3 | 5.4 | 12.0 | 17.7 | 24.4 | 5.6 | +3.7 | 11.0 | (8.3) | 16.9 | (4.5) | - | - | 11.0 | (8.3) | 21.9 | (10.2) |
| Overseas | 33.5 | 33.6 | 7.4 | 18.1 | 26.1 | 33.0 | 5.9 | (20.3) | 19.3 | +6.6 | 33.4 | +28.0 | - | - | 19.3 | +6.6 | 37.2 | +12.7 |
| Actemra | 3.8 | 8.9 | 2.0 | 7.4 | 10.5 | 12.7 | 1.4 | (30.0) | 9.1 | +23.0 | 18.8 | +79.0 | - | - | 9.1 | +23.0 | 19.7 | +55.1 |
| Neutrogin | 25.9 | 21.3 | 4.4 | 8.8 | 13.0 | 17.0 | 3.5 | (20.5) | 8.1 | (8.0) | 11.7 | (10.0) | - | - | 8.1 | (8.0) | 14.1 | (17.1) |
| Sigmart | 2.0 | 1.9 | 0.8 | 1.3 | 1.8 | 2.2 | 0.6 | (25.0) | 1.2 | (7.7) | 1.7 | (5.6) | - | - | 1.2 | (7.7) | 2.2 | +0.0 |
| Other products | 1.7 | 1.5 | 0.2 | 0.5 | 0.8 | 1.2 | 0.5 | +150.0 | 0.9 | +80.0 | 1.2 | +50.0 | - | - | 0.9 | +80.0 | 1.1 | (8.3) |
| Tamiflu | 8.4 | 76.2 | 10.8 | 12.0 | 15.8 | 18.2 | 4.2 | (61.1) | 4.6 | (61.7) | 6.3 | (60.1) | - | - | 4.6 | (61.7) | 10.2 | (44.0) |
| Ordinary sales | 7.1 | 36.2 | 1.4 | 1.4 | 1.4 | 1.6 | 3.7 | +164.3 | 4.1 | +192.9 | 4.1 | +192.9 | - | - | 4.1 | +192.9 | 6.7 | +318.8 |
| Govt. stockpile etc. | 1.3 | 40.0 | 9.5 | 10.6 | 14.4 | 16.6 | 0.5 | (94.7) | 0.5 | (95.3) | 2.2 | (84.7) | - | - | 0.5 | (95.3) | 3.5 | (78.9) |
| Other operating revenues | 5.1 | 9.8 | 0.9 | 1.7 | 2.8 | 3.9 | 5.3 | +488.9 | 7.2 | +323.5 | 8.5 | +203.6 | - | - | 7.2 | +323.5 | 10.7 | +174.4 |
| Revenues (total) | 326.9 | 428.9 | 87.1 | 182.4 | 276.1 | 379.5 | 85.7 | (1.6) | 181.9 | (0.3) | 276.0 | (0.0) | - | - | 181.9 | (0.3) | 395.2 | +4.1 |
| Domestic | 293.1 | 392.6 | 78.9 | 162.8 | 247.5 | 342.9 | 77.7 | (1.5) | 159.0 | (2.3) | 237.8 | (3.9) | - | - | 159.0 | (2.3) | 351.2 | +2.4 |
| Overseas | 33.8 | 36.4 | 8.2 | 19.6 | 28.6 | 36.6 | 8.0 | (2.4) | 22.9 | +16.8 | 38.2 | +33.6 | - | - | 22.9 | +16.8 | 44.0 | +20.2 |

Note: Edirol (launched in April 2011), Mircera (launched in July 2011)

Statements of Revenues (QTR)

(Billions of Yen)

| | FY2008 | FY2009 | FY2010 | | | | FY2011 | | | | | | | Revised Forecast (released on July 21) | | | | |
|--|--------|--------|--------|------|--------|-------|--------|------------|------|------------|------|------------|-------|--|------------------|------------|-------|------------|
| | | | FY2010 | | FY2011 | | | | | FY2011 | | | | | | | | |
| | | | 1-3 | 4-6 | 7-9 | 10-12 | 1-3 | Change (%) | 4-6 | Change (%) | 7-9 | Change (%) | 10-12 | Change (%) | 1-6 | Change (%) | 7-12 | Change (%) |
| | | | 1-12 | 1-12 | QTR | QTR | QTR | QTR | QTR | QTR | QTR | QTR | QTR | QTR | 1st Half(Actual) | 2nd Half | | |
| Sales | 321.8 | 419.1 | 86.2 | 94.5 | 92.6 | 102.3 | 80.4 | (6.7) | 94.4 | (0.1) | 92.7 | +0.1 | - | - | 174.8 | (3.2) | 209.7 | +7.6 |
| Excl. Tamiflu | 313.4 | 342.9 | 75.4 | 93.3 | 88.8 | 100.0 | 76.2 | +1.1 | 94.0 | +0.8 | 91.0 | +2.5 | - | - | 170.2 | +0.9 | 204.2 | +8.2 |
| Domestic | 279.9 | 309.3 | 68.0 | 82.6 | 80.8 | 93.0 | 70.2 | +3.2 | 80.6 | (2.4) | 76.9 | (4.8) | - | - | 150.9 | +0.2 | 186.3 | +7.2 |
| Oncology field | 102.3 | 123.7 | 28.8 | 35.7 | 35.5 | 41.1 | 31.0 | +7.6 | 36.8 | +3.1 | 33.7 | (5.1) | - | - | 67.9 | +5.1 | 82.7 | +8.0 |
| Avastin | 20.1 | 34.9 | 10.3 | 13.0 | 13.5 | 15.8 | 12.5 | +21.4 | 13.9 | +6.9 | 13.8 | +2.2 | - | - | 26.4 | +13.3 | 36.0 | +22.4 |
| Herceptin | 23.7 | 29.7 | 5.7 | 6.4 | 6.2 | 6.9 | 5.6 | (1.8) | 8.3 | +29.7 | 4.8 | (22.6) | - | - | 13.9 | +14.9 | 10.7 | (18.3) |
| Rituxan | 20.5 | 21.1 | 4.5 | 5.8 | 5.8 | 6.9 | 4.9 | +8.9 | 5.5 | (5.2) | 5.8 | +0.0 | - | - | 10.4 | +1.0 | 13.1 | +3.1 |
| Xeloda | 4.8 | 6.6 | 2.3 | 2.8 | 2.7 | 2.9 | 2.3 | +0.0 | 2.6 | (7.1) | 2.5 | (7.4) | - | - | 4.9 | (3.9) | 6.8 | +21.4 |
| Neutrogin | 12.0 | 11.3 | 2.0 | 2.6 | 2.6 | 3.3 | 1.8 | (10.0) | 2.3 | (11.5) | 2.5 | (3.8) | - | - | 4.1 | (10.9) | 6.0 | +1.7 |
| Tarceva | 4.5 | 5.8 | 1.4 | 2.0 | 2.0 | 2.4 | 1.7 | +21.4 | 2.1 | +5.0 | 2.0 | +0.0 | - | - | 3.8 | +8.6 | 5.1 | +15.9 |
| Femara | 1.7 | 2.4 | 0.6 | 0.8 | 0.8 | 1.0 | 0.8 | +33.3 | 0.9 | +12.5 | 0.9 | +12.5 | - | - | 1.7 | +21.4 | 2.1 | +16.7 |
| Kytril | 10.9 | 8.6 | 1.5 | 1.5 | 1.3 | 1.2 | 0.8 | (46.7) | 0.9 | (40.0) | 0.8 | (38.5) | - | - | 1.7 | (43.3) | 2.0 | (20.0) |
| Other products | 4.1 | 3.3 | 0.6 | 0.7 | 0.6 | 0.7 | 0.5 | (16.7) | 0.5 | (28.6) | 0.5 | (16.7) | - | - | 1.0 | (23.1) | 1.0 | (23.1) |
| Bone and joint diseases field | 50.0 | 57.6 | 13.0 | 15.7 | 15.4 | 18.5 | 14.0 | +7.7 | 16.4 | +4.5 | 16.8 | +9.1 | - | - | 30.4 | +6.3 | 38.6 | +13.5 |
| Actemra | 3.4 | 8.4 | 2.6 | 3.3 | 3.6 | 4.7 | 3.5 | +34.6 | 4.1 | +24.2 | 4.5 | +25.0 | - | - | 7.6 | +31.0 | 12.2 | +48.8 |
| Evista | 16.5 | 17.9 | 3.8 | 4.8 | 4.5 | 5.6 | 3.8 | +0.0 | 4.6 | (4.2) | 4.8 | +6.7 | - | - | 8.4 | (2.3) | 9.0 | (10.9) |
| Suvenyl | 12.0 | 13.7 | 2.9 | 3.5 | 3.3 | 3.9 | 2.6 | (10.3) | 3.4 | (2.9) | 3.3 | +0.0 | - | - | 6.0 | (6.3) | 7.7 | +6.9 |
| Alfarol | 13.7 | 13.6 | 2.7 | 3.2 | 2.9 | 3.5 | 2.6 | (3.7) | 2.8 | (12.5) | 2.8 | (3.4) | - | - | 5.4 | (8.5) | 5.7 | (10.9) |
| Ediol | - | - | - | - | - | - | - | - | 0.6 | - | 0.2 | - | - | - | 0.6 | - | 1.5 | - |
| Other products | 4.5 | 3.9 | 1.0 | 0.9 | 1.1 | 0.9 | 1.5 | +50.0 | 0.9 | +0.0 | 1.2 | +9.1 | - | - | 2.4 | +26.3 | 2.4 | +20.0 |
| Renal diseases field | 61.3 | 61.0 | 12.5 | 14.7 | 14.6 | 15.6 | 11.4 | (8.8) | 12.9 | (12.2) | 12.6 | (13.7) | - | - | 24.3 | (10.7) | 34.6 | +14.6 |
| Epogin | 44.9 | 44.4 | 8.7 | 10.3 | 10.2 | 10.8 | 7.5 | (13.8) | 9.1 | (11.7) | 6.0 | (41.2) | - | - | 16.6 | (12.6) | 13.9 | (33.8) |
| Mircera | - | - | - | - | - | - | - | - | - | - | 2.8 | - | - | - | - | - | 12.4 | - |
| Oxarol | 10.0 | 10.6 | 2.5 | 3.1 | 3.0 | 3.4 | 2.8 | +12.0 | 3.0 | (3.2) | 3.0 | +0.0 | - | - | 5.8 | +3.6 | 6.7 | +4.7 |
| Renagel | 5.7 | 5.3 | 1.1 | 1.2 | 1.2 | 1.3 | 1.1 | +0.0 | 0.7 | (41.7) | 0.6 | (50.0) | - | - | 1.7 | (26.1) | 1.3 | (48.0) |
| Other products | 0.7 | 0.7 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | (50.0) | 0.1 | +0.0 | 0.2 | +100.0 | - | - | 0.2 | (33.3) | 0.3 | +50.0 |
| Transplant, Immunology & Infectious diseases field | 24.0 | 26.2 | 5.3 | 6.6 | 6.4 | 7.4 | 5.5 | +3.8 | 6.0 | (9.1) | 5.4 | (15.6) | - | - | 11.5 | (3.4) | 13.6 | (2.2) |
| Pegasys | 9.7 | 11.1 | 2.2 | 2.6 | 2.6 | 3.0 | 2.2 | +0.0 | 2.3 | (11.5) | 1.9 | (26.9) | - | - | 4.4 | (8.3) | 5.9 | +3.5 |
| Copegus | 4.2 | 4.9 | 0.9 | 1.1 | 1.1 | 1.3 | 0.9 | +0.0 | 1.0 | (9.1) | 0.7 | (36.4) | - | - | 1.9 | (5.0) | 2.5 | +4.2 |
| CellCept | 4.0 | 4.4 | 1.0 | 1.3 | 1.3 | 1.5 | 1.2 | +20.0 | 1.4 | +7.7 | 1.4 | +7.7 | - | - | 2.6 | +13.0 | 3.1 | +10.7 |
| Rocephin | 5.9 | 5.5 | 1.1 | 1.5 | 1.4 | 1.5 | 1.1 | +0.0 | 1.3 | (13.3) | 1.3 | (7.1) | - | - | 2.4 | (7.7) | 2.0 | (28.6) |
| Other products | 0.3 | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | +0.0 | 0.1 | +0.0 | 0.1 | +0.0 | - | - | 0.2 | +100.0 | 0.1 | (50.0) |
| Others field | 42.3 | 40.9 | 8.3 | 9.9 | 8.8 | 10.3 | 8.3 | +0.0 | 8.4 | (15.2) | 8.4 | (4.5) | - | - | 16.8 | (8.2) | 16.8 | (12.5) |
| Sigmat | 15.0 | 14.7 | 2.9 | 3.4 | 3.0 | 3.7 | 2.7 | (6.9) | 3.0 | (11.8) | 2.6 | (13.3) | - | - | 5.7 | (9.5) | 5.9 | (11.9) |
| Other products | 27.3 | 26.3 | 5.4 | 6.5 | 5.8 | 6.7 | 5.6 | +3.7 | 5.4 | (16.9) | 5.9 | +1.7 | - | - | 11.0 | (8.3) | 10.9 | (12.8) |
| Overseas | 33.5 | 33.6 | 7.4 | 10.7 | 8.0 | 6.9 | 5.9 | (20.3) | 13.4 | +25.2 | 14.1 | +76.3 | - | - | 19.3 | +6.6 | 17.9 | +19.3 |
| Actemra | 3.8 | 8.9 | 2.0 | 5.4 | 3.1 | 2.2 | 1.4 | (30.0) | 7.7 | +42.6 | 9.7 | +212.9 | - | - | 9.1 | +23.0 | 10.6 | +100.0 |
| Neutrogin | 25.9 | 21.3 | 4.4 | 4.4 | 4.2 | 4.0 | 3.5 | (20.5) | 4.6 | +4.5 | 3.6 | (14.3) | - | - | 8.1 | (8.0) | 6.0 | (26.8) |
| Sigmat | 2.0 | 1.9 | 0.8 | 0.6 | 0.4 | 0.4 | 0.6 | (25.0) | 0.6 | +0.0 | 0.5 | +25.0 | - | - | 1.2 | (7.7) | 1.0 | +11.1 |
| Other products | 1.7 | 1.5 | 0.2 | 0.3 | 0.3 | 0.3 | 0.5 | +150.0 | 0.4 | +33.3 | 0.3 | +0.0 | - | - | 0.9 | +80.0 | 0.3 | (50.0) |
| Tamiflu | 8.4 | 76.2 | 10.8 | 1.2 | 3.8 | 2.3 | 4.2 | (61.1) | 0.4 | (66.7) | 1.7 | (55.3) | - | - | 4.6 | (61.7) | 5.6 | (8.2) |
| Ordinary sales | 7.1 | 36.2 | 1.4 | 0.0 | 0.0 | 0.2 | 3.7 | +164.3 | 0.4 | - | 0.0 | - | - | - | 4.1 | +192.9 | 2.6 | +1,200.0 |
| Govt. stockpile etc. | 1.3 | 40.0 | 9.5 | 1.2 | 3.8 | 2.1 | 0.5 | (94.7) | - | (100.0) | 1.7 | (55.3) | - | - | 0.5 | (95.3) | 3.0 | (49.2) |
| Other operating revenues | 5.1 | 9.8 | 0.9 | 0.8 | 1.1 | 1.1 | 5.3 | +488.9 | 1.8 | +125.0 | 1.4 | +27.3 | - | - | 7.2 | +323.5 | 3.5 | +59.1 |
| Revenues (total) | 326.9 | 428.9 | 87.1 | 95.3 | 93.7 | 103.4 | 85.7 | (1.6) | 96.2 | +0.9 | 94.1 | +0.4 | - | - | 181.9 | (0.3) | 213.3 | +8.2 |
| Domestic | 293.1 | 392.6 | 78.9 | 83.9 | 84.7 | 95.5 | 77.7 | (1.5) | 81.3 | (3.1) | 78.8 | (7.0) | - | - | 159.0 | (2.3) | 192.2 | +6.7 |
| Overseas | 33.8 | 36.4 | 8.2 | 11.4 | 9.0 | 8.0 | 8.0 | (2.4) | 14.9 | +30.7 | 15.3 | +70.0 | - | - | 22.9 | +16.8 | 21.0 | +23.5 |

Balance Sheets

(Billions of Yen)

| | FY2008 | FY2009 | FY2010 | | | | FY2011 | | | | | |
|--|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|----------------------|----------------------|------------------|
| | As of Dec. 31 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | vs. Sep. 30, 2010 | vs. Dec. 31, 2010 | As of Dec. 31 |
| Cash and deposits | 70.8 | 107.0 | 101.1 | 81.3 | 70.2 | 76.2 | 101.7 | 109.2 | 110.7 | +40.5 | +34.5 | - |
| Trade notes and accounts receivable | 108.5 | 121.6 | 85.4 | 99.2 | 99.3 | 113.4 | 94.6 | 105.8 | 98.4 | (0.9) | (15.0) | - |
| Marketable securities | 54.7 | 52.2 | 55.7 | 61.7 | 58.7 | 59.7 | 58.0 | 59.0 | 59.0 | +0.3 | (0.7) | - |
| Inventories | 78.7 | 92.6 | 100.0 | 111.7 | 115.9 | 104.9 | 108.5 | 110.4 | 115.7 | (0.2) | +10.8 | - |
| Other current assets | 31.7 | 37.9 | 41.7 | 29.5 | 35.0 | 32.3 | 39.7 | 27.6 | 33.9 | (1.1) | +1.6 | - |
| Total Current assets | 344.4 | 411.3 | 383.9 | 383.4 | 379.1 | 386.5 | 402.5 | 412.1 | 417.7 | +38.6 | +31.2 | - |
| Property, plant and equipment | 98.3 | 93.7 | 91.4 | 89.8 | 88.4 | 88.0 | 86.1 | 83.5 | 81.8 | (6.6) | (6.2) | - |
| Intangible assets | 3.1 | 3.2 | 3.0 | 2.6 | 2.6 | 2.4 | 2.3 | 2.4 | 2.1 | (0.5) | (0.3) | - |
| Investments and other assets | 32.7 | 32.3 | 32.9 | 31.4 | 31.1 | 31.2 | 29.3 | 31.3 | 32.8 | +1.7 | +1.6 | - |
| thereof Investment securities | 14.4 | 9.7 | 9.5 | 8.0 | 7.3 | 7.6 | 7.0 | 6.9 | 6.9 | (0.4) | (0.7) | - |
| Total Noncurrent Assets | 134.2 | 129.2 | 127.2 | 123.8 | 122.1 | 121.5 | 117.8 | 117.3 | 116.7 | (5.4) | (4.8) | - |
| Total Assets | 478.5 | 540.5 | 511.1 | 507.2 | 501.2 | 508.0 | 520.3 | 529.4 | 534.4 | +33.2 | +26.4 | - |
| Trade notes and accounts payable | 28.8 | 34.3 | 35.4 | 32.2 | 26.2 | 19.5 | 29.5 | 28.5 | 29.2 | +3.0 | +9.7 | - |
| Short-term loans and bonds | - | - | - | - | - | - | - | - | - | - | - | - |
| Other current liabilities | 49.8 | 66.2 | 42.2 | 36.3 | 33.2 | 35.1 | 42.4 | 40.3 | 48.1 | +14.9 | +13.0 | - |
| Total current liabilities | 78.5 | 100.5 | 77.6 | 68.5 | 59.4 | 54.6 | 72.0 | 68.8 | 77.3 | +17.9 | +22.7 | - |
| Long-term debt and bonds | - | - | - | - | - | - | - | - | - | - | - | - |
| Other noncurrent liabilities | 2.9 | 5.4 | 5.2 | 4.8 | 5.0 | 4.0 | 5.3 | 5.3 | 5.4 | +0.4 | +1.4 | - |
| Total noncurrent liabilities | 2.9 | 5.4 | 5.2 | 4.8 | 5.0 | 4.0 | 5.3 | 5.3 | 5.4 | +0.4 | +1.4 | - |
| Total liabilities | 81.5 | 105.9 | 82.8 | 73.3 | 64.4 | 58.6 | 77.3 | 74.1 | 82.8 | +18.4 | +24.2 | - |
| Common stock | 73.0 | 73.0 | 73.0 | 73.0 | 73.0 | 73.0 | 73.0 | 73.0 | 73.0 | - | - | - |
| Additional paid-in capital | 92.8 | 92.8 | 92.8 | 92.8 | 92.8 | 92.8 | 92.8 | 92.8 | 92.8 | - | - | - |
| Retained earnings | 271.0 | 308.0 | 303.3 | 311.8 | 314.3 | 327.6 | 320.1 | 332.2 | 331.4 | +17.1 | +3.8 | - |
| Treasury stock, at cost | (35.2) | (36.3) | (36.3) | (36.3) | (36.3) | (36.3) | (36.3) | (36.3) | (36.3) | +0.0 | +0.0 | - |
| Net unrealized gain on securities | 1.4 | 1.6 | 1.8 | 1.5 | 1.2 | 1.3 | 1.0 | 0.9 | 1.1 | (0.1) | (0.2) | - |
| Foreign currency translation adjustments | (7.9) | (6.8) | (8.2) | (11.1) | (10.1) | (11.3) | (9.5) | (9.7) | (12.2) | (2.1) | (0.9) | - |
| New share warrants | 0.3 | 0.5 | 0.6 | 0.6 | 0.7 | 0.8 | 0.8 | 0.9 | 0.9 | +0.2 | +0.1 | - |
| Minority interests | 1.7 | 1.8 | 1.3 | 1.4 | 1.2 | 1.4 | 1.0 | 1.4 | 1.0 | (0.2) | (0.4) | - |
| Total net assets | 397.1 | 434.7 | 428.4 | 433.9 | 436.7 | 449.4 | 443.0 | 455.3 | 451.6 | +14.9 | +2.2 | - |
| Total liabilities and net assets | 478.5 | 540.5 | 511.1 | 507.2 | 501.2 | 508.0 | 520.3 | 529.4 | 534.4 | +33.2 | +26.4 | - |

Cash Flows

(Billions of Yen)

| | FY2008 | FY2009 | FY2010 | | | | FY2011 | | | |
|--|-----------|-----------|--------|--------|--------|-----------|--------|--------|--------|-----------|
| | 1-12 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 |
| | Full-year | Full-year | YTD | YTD | YTD | Full-year | YTD | YTD | YTD | Full-year |
| Net cash provided by (used in) operating activities | 39.3 | 66.5 | 16.4 | 6.8 | 4.4 | 15.6 | 39.6 | 50.2 | 67.8 | - |
| Net cash provided by (used in) investing activities | (14.1) | (20.3) | 1.2 | (16.6) | (16.2) | (20.2) | (0.8) | (3.7) | (6.4) | - |
| Net cash provided by (used in) financing activities | (18.4) | (22.3) | (13.2) | (13.2) | (23.1) | (23.1) | (13.2) | (13.2) | (24.3) | - |
| Effect of exchange rate changes on cash and cash equivalents | (9.9) | (0.1) | (0.6) | (1.5) | (1.2) | (1.7) | 0.7 | 0.6 | (0.7) | - |
| Net increase (decrease) in cash and cash equivalents | (3.1) | 23.8 | 3.8 | (24.5) | (36.1) | (29.3) | 26.4 | 34.0 | 36.5 | - |
| Cash and cash equivalents at beginning of period | 73.7 | 70.7 | 94.5 | 94.5 | 94.5 | 94.5 | 65.1 | 65.1 | 65.1 | - |
| Cash and cash equivalents at end of period | 70.7 | 94.5 | 98.2 | 69.9 | 58.4 | 65.1 | 91.6 | 99.1 | 101.7 | - |

Performance Indicators

| | FY2008 | FY2009 | FY2010 | | | | FY2011 | | | | Revised Forecast (released on July 21) |
|---|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---|
| | 1-12 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | FY2011 |
| | As of Dec. 31 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Dec. 31 |
| Net income per share (Basic) | 72.07yen | 104.00yen | 14.43yen | 30.09yen | 51.55yen | 76.14yen | 9.17yen | 31.40yen | 49.85yen | - | 67.99yen |
| Net income per share (Fully diluted) | 72.04yen | 103.98yen | 14.43yen | 30.09yen | 51.54yen | 76.12yen | 9.17yen | 31.39yen | 49.84yen | - | - |
| Ratio of net income to shareholders' equity * | 10.1% | 13.7% | 1.8% | 3.8% | 6.5% | 9.4% | 1.1% | 3.8% | 6.0% | - | - |
| Ratio of ordinary income to total assets * | 12.2% | 17.7% | 2.3% | 5.0% | 8.5% | 12.4% | 3.2% | 7.0% | 9.8% | - | - |
| Net assets per share | 725.18yen | 794.51yen | 783.67yen | 793.50yen | 799.11yen | 821.87yen | 810.62yen | 832.45yen | 826.39yen | - | - |
| Equity ratio | 82.6% | 80.0% | 83.4% | 85.1% | 86.8% | 88.0% | 84.8% | 85.6% | 84.2% | - | - |
| Dividend per share (Annual) | 34yen | 40yen | | | | 40yen | | | | - | 40yen |
| Dividend per share (Interim) | 15yen | 17yen | | | | 17yen | | | | 20yen | 20yen |
| Dividend payout ratio (Consolidated) | 47.2% | 38.5% | | | | 52.5% | | | | - | 58.8% |

Note: Quarterly (year-to-date) Ratio of net income to shareholders' equity and Ratio of ordinary income to total assets are not annualized.

Number of Employees

| | FY2008 | FY2009 | FY2010 | | | | FY2011 | | | | Revised Forecast (released on July 21) |
|---------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---|
| | As of Dec. 31 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | FY2011 |
| | As of Dec. 31 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Dec. 31 |
| Number of employees | 6,383 | 6,485 | 6,472 | 6,707 | 6,723 | 6,709 | 6,635 | 6,818 | 6,812 | - | 6,830 |

Note: Number of employees doesn't include staff seconded to companies outside the Group.

Capital Expenditures

(Billions of Yen)

| | FY2008 | FY2009 | FY2010 | | | | FY2011 | | | | Revised Forecast (released on July 21) |
|----------------------|-----------|-----------|--------|-----|------|-----------|--------|-----|------|-----------|---|
| | 1-12 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | FY2011 |
| | Full-year | Full-year | YTD | YTD | YTD | Full-year | YTD | YTD | YTD | Full-year | Full-year |
| Capital expenditures | 26.6 | 14.6 | 1.8 | 4.6 | 7.9 | 12.7 | 1.4 | 4.6 | 6.4 | - | 13.0 |
| Depreciation | 19.4 | 19.5 | 4.1 | 8.4 | 13.0 | 18.0 | 3.8 | 7.2 | 11.4 | - | 16.0 |

Development pipeline (as of October 21, 2011)

| Development code | Indication # Additional indication | Stage (date) | Generic name Product name Dosage form | Origin Overseas name (Collaborator) | Mode of Action |
|-------------------|--|----------------------------------|---|---|--|
| Oncology | | | | | |
| RG435 | Breast cancer # | Approved Sep 11. | bevacizumab Avastin Injection | Roche Avastin | Anti-VEGF(Vascular Endothelial Growth Factor) humanized monoclonal antibody |
| | Gastric cancer # | Phase III Multinational study | | | |
| | Breast cancer (adjuvant) # | Phase III Multinational study | | | |
| | Glioblastoma # | Phase III Multinational study | | | |
| | Glioblastoma (relapsed) # | Phase II | | | |
| RG1415 | Pancreatic cancer # | Approved Jul. 11 | erlotinib HCl Tarceva Oral | Roche/OSI Tarceva | EGFR tyrosine kinase inhibitor |
| | Non-small cell lung cancer (1st line) # | Phase II | | | |
| EPOCH | Chemotherapy-induced anemia # | Filed Nov. 09 | epoetin beta Epogin Injection | In-house | Recombinant human erythropoietin |
| RG1273 | Breast cancer | Phase III Multinational study | pertuzumab Injection | Roche | Humanized HER dimerization inhibitory monoclonal antibody |
| RG3502 | Breast cancer | Phase III Multinational study | Injection | Roche | HER2 antibody-drug conjugate (T-DM1) |
| GA101 (RG7159) | Indolent NHL | Phase III Multinational study | Injection | Roche | Humanized anti-CD20 monoclonal antibody |
| | Aggressive NHL | Phase III Multinational study | | | |
| MRA | Pancreatic cancer # | Phase I / II | tocilizumab Actemra Injection | In-house | Humanized anti-human IL-6 receptor monoclonal antibody |

| Development code | Indication # Additional indication | Stage (date) | Generic name Product name Dosage form | Origin Overseas name (Collaborator) | Mode of Action |
|--------------------------------|--|---------------------------|--|---|--|
| AF802 | Non-small cell lung cancer | Phase I / II | Oral | In-house | ALK inhibitor |
| WT4869 | Myelodysplastic syndromes | Phase I / II | Injection | In-house / Dainippon Sumitomo Pharma | WT1 peptide cancer vaccine |
| | Solid tumors | Phase I | | | |
| CIF (RG7167) | Solid tumors | Phase I | Oral | In-house (Roche) | MEK inhibitor |
| | | Phase I Overseas | | | |
| CKI27 (RG7304) | Solid tumors | Phase I | Oral | In-house (Roche) | Raf and MEK dual inhibitor |
| | | Phase I Overseas | | | |
| GC33 | Liver cancer | Phase I | Injection | In-house (Roche) | Humanized anti-Glypican-3 monoclonal antibody |
| | | Phase I Overseas | | | |
| PA799 | Solid tumors | Phase I Overseas | Oral | In-house | - |
| RG3638 | Non-small cell lung cancer | Phase I | Injection | Roche | Humanized anti-Met antibody |
| Bone and Joint Diseases | | | | | |
| MRA | Systemic-onset juvenile idiopathic arthritis (sJIA) # | Approved Aug. 11 EU | tocilizumab Actemra / RoActemra(EU) Injection | In-house (Roche) | Humanized anti-human IL-6 receptor monoclonal antibody |
| | Rheumatoid arthritis (new formulation: subcutaneous injection) | Phase III | | | |
| | | Phase III Overseas | | | |

| Development code | Indication # Additional indication | Stage (date) | Generic name Product name Dosage form | Origin Overseas name (Collaborator) | Mode of Action |
|---|---|----------------------------------|---|---|--|
| RG484 | Osteoporosis | Phase II / III | ibandronate sodium hydrate Injection | Roche Boniva (US) / Bonviva (EU) (Taisho Pharmaceutical) | Bisphosphonate |
| | | Phase II | ibandronate sodium hydrate Oral | | |
| SA237 | Rheumatoid arthritis | Phase I | Injection | In-house | Humanized anti-human IL-6 receptor monoclonal antibody |
| Renal Diseases | | | | | |
| RG744 | Renal anemia | Launched Jul. 11 | Epoetin beta pegol Mircera Injection | Roche Mircera | Continuous erythropoietin receptor activator |
| Transplant, Immunology and Infectious Diseases | | | | | |
| RG964 | Compensated liver cirrhosis caused by hepatitis C virus | Approved Jul. 11 | ribavirin Copegus Oral | Roche Copegus | Anti-viral agent, in combination with Pegasys |
| RG442 | # Chronic hepatitis B | | Approved Sep. 11 | peginterferon alfa-2a Pegasys Injection | Roche Pegasys |
| RG7128 | # Chronic hepatitis C | Phase I | mericitabine Oral | Roche | Polymerase inhibitor |
| Other Diseases | | | | | |
| CSG452 | Type II diabetes | Phase III | tofogliflozin hydrate Oral | In-house | SGLT2 inhibitor |
| RG1678 | Schizophrenia | Phase III Multinational study | Oral | Roche | Glycine reuptake inhibitor |
| RG1450 | Alzheimer's disease | Phase I | gantenerumab Injection | Roche/Morphosys | Human anti-amyloid-beta monoclonal antibody |
| RG7090 | Major depressive disorder | Phase I | Oral | Roche | mGluR5 antagonist |

| Development code | Indication # Additional indication | Stage (date) | Generic name Product name Dosage form | Origin Overseas name (Collaborator) | Mode of Action |
|------------------|---------------------------------------|-----------------|---|---|-------------------------------|
| RG3637 | Asthma | Phase I | Injection | Roche | Humanized anti-IL-13 antibody |

Changes from the last announcement on July 21, 2011

Oncology

-RG435 (Avastin) Filed → Approved (Breast cancer)
 -GA101 Phase I → Phase III Multinational study (Indolent NHL, Aggressive NHL)
 -WT4869 Phase I (Solid tumors: Starting development)
 -RG3638 Phase I (Non-small cell lung cancer: Starting development)

Bone and Joint Diseases

-MRA (RoActemra) Filed → Approved (Systemic-onset juvenile idiopathic arthritis (sJIA) / EU)

Transplant, Immunology and Infectious Diseases

-RG442 (Pegasys) Filed → Approved (Chronic hepatitis B)

Other Diseases

-RG3637 Phase I (Asthma: Starting development)

R&D Activities (Jul. 1, 2011 – Oct. 21, 2011)

As for clinical development activities in Japan, the Company saw progress as described below:

Oncology

- In September, we obtained an approval for an additional indication of a humanized anti-VEGF monoclonal antibody, RG435 (product name: Avastin), for Breast cancer.
- In July, we obtained an approval for an additional indication of an EGFR tyrosine kinase inhibitor, RG1415 (product name: Tarceva) for Pancreatic cancer.
- We decided to participate in the Phase III multinational studies (expected indication: Indolent NHL, Aggressive NHL) conducted by Roche for a humanized anti-CD20 monoclonal antibody, GA101. The patient enrollment in Japan is planned to commence within the year.
- In September, we started a Phase I study (expected indication: Solid tumors) for a WT1 peptide cancer vaccine, WT4869.
- In August, we started a Phase I study (expected indication: Non-small cell lung cancer) for a humanized anti-Met antibody, RG3638.

Renal Diseases

- In July, we launched a continuous erythropoietin receptor activator, RG744 (product name: Mircera), for Renal anemia.

Transplant, Immunology and Infectious Diseases

- In July, we obtained an approval for an additional indication of an anti-viral agent, RG964 (Product name: Copegus), in combination with a peginterferon alfa-2a agent (recombinant), RG442 (product name: Pegasys), for Compensated liver cirrhosis caused by hepatitis C virus.
- In September, we obtained an approval for an additional indication of a peginterferon alfa-2a agent (recombinant), RG442 (product name: Pegasys), for Chronic hepatitis B.

Other Diseases

- In August, we started a Phase I study (expected indication: Asthma) for a humanized anti-IL-13 antibody, RG3637.

Also, as for development activities overseas, the Company saw progress as described below:

- In August, Roche obtained an approval for an additional indication of a humanized anti-human IL-6 receptor monoclonal antibody, MRA (product name: RoActemra), for Systemic-onset juvenile idiopathic arthritis (sJIA) in EU.

Major clinical trials in oncology field currently running in Japan

| Theme | Expected Indication | Regimen | Stage | Planned Filing Date |
|-----------------------------------|--|---|---|---------------------|
| RG435 (bevacizumab) Avastin | Breast cancer | paclitaxel + RG435 | Approved (Sep. 11) | - |
| | Breast cancer (adjuvant) | standard chemotherapy ± RG435 | BEATRICE study Phase III Multinational study | Post 2014 |
| | Glioblastoma | temozolomide ± RG435 | Phase III Multinational study | Post 2014 |
| | Glioblastoma [relapsed] | RG435 | AVAglio study Phase II | Post 2014 |
| RG1415 (erlotinib HCl) Tarceva | Pancreatic cancer | gemcitabine + RG1415 | Approved (Jul. 11) | - |
| | Non-small cell lung cancer (1st line) | RG1415 | Phase II | 2012 |
| RG1273 (pertuzumab) | Breast cancer | RG597 + docetaxel ± RG1273 | CLEOPATRA study Phase III Multinational study | 2012 |
| RG3502 (T-DM1) | Breast cancer | RG3502 | MARIANNE study Phase III Multinational study | 2013 |
| GA101(RG7159) | Indolent NHL | GA101 + chemo vs Rituximab + chemo (G-chemo vs R-chemo) | GALLIUM study Phase III Multinational study | Post 2014 |
| | Aggressive NHL | GA101 + CHOP vs Rituximab + CHOP (G-CHOP vs R-CHOP) | GOYA study Phase III Multinational study | Post 2014 |